AAAAAA

   
Results: 1-12 |
Results: 12
Development of dendritic cell-based prostate cancer vaccine
Authors: Tjoa, BA Murphy, GP
Citation: Ba. Tjoa et Gp. Murphy, Development of dendritic cell-based prostate cancer vaccine, CONT CANC R, 2001, pp. 449-459
Progress in active specific immunotherapy of prostate cancer
Authors: Tjoa, BA Murphy, GP
Citation: Ba. Tjoa et Gp. Murphy, Progress in active specific immunotherapy of prostate cancer, SEM SURG ON, 18(1), 2000, pp. 80-87
Progress in active-specific immunotherapy of brain malignancies
Authors: Tjoa, BA Salgaller, ML
Citation: Ba. Tjoa et Ml. Salgaller, Progress in active-specific immunotherapy of brain malignancies, EXPERT OP I, 9(9), 2000, pp. 2093-2101
Higher-dose and less frequent dendritic cell infusions with PSMA peptides in hormone-refractory metastatic prostate cancer patients
Authors: Murphy, GP Tjoa, BA Simmons, SJ Rogers, MK Kenny, GM Jarisch, J
Citation: Gp. Murphy et al., Higher-dose and less frequent dendritic cell infusions with PSMA peptides in hormone-refractory metastatic prostate cancer patients, PROSTATE, 43(1), 2000, pp. 59-62
Use of artificial neural networks in evaluating prognostic factors determining the response to dendritic cells pulsed with PSMA peptides in prostate cancer patients
Authors: Murphy, GP Snow, P Simmons, SJ Tjoa, BA Rogers, MK Brandt, J Healy, CG Bolton, WE Rodbold, D
Citation: Gp. Murphy et al., Use of artificial neural networks in evaluating prognostic factors determining the response to dendritic cells pulsed with PSMA peptides in prostate cancer patients, PROSTATE, 42(1), 2000, pp. 67-72
Development of dendritic-cell based prostate cancer vaccine
Authors: Tjoa, BA Murphy, GP
Citation: Ba. Tjoa et Gp. Murphy, Development of dendritic-cell based prostate cancer vaccine, IMMUNOL LET, 74(1), 2000, pp. 87-93
Follow-up evaluation of a phase II prostate cancer vaccine trial
Authors: Tjoa, BA Simmons, SJ Elgamal, A Rogers, M Ragde, H Kenny, GM Troychak, MJ Boynton, AL Murphy, GP
Citation: Ba. Tjoa et al., Follow-up evaluation of a phase II prostate cancer vaccine trial, PROSTATE, 40(2), 1999, pp. 125-129
GM-CSF as a systemic adjuvant in a phase II prostate cancer vaccine trial
Authors: Simmons, SJ Tjoa, BA Rogers, M Elgamal, A Kenny, GM Ragde, H Troychak, MJ Boynton, AL Murphy, GP
Citation: Sj. Simmons et al., GM-CSF as a systemic adjuvant in a phase II prostate cancer vaccine trial, PROSTATE, 39(4), 1999, pp. 291-297
Phase II prostate cancer vaccine trial: Report of a study involving 37 patients with disease recurrence following primary treatment
Authors: Murphy, GP Tjoa, BA Simmons, SJ Ragde, H Rogers, M Elgamal, A Kenny, GM Troychak, MJ Salgaller, ML Boynton, AL
Citation: Gp. Murphy et al., Phase II prostate cancer vaccine trial: Report of a study involving 37 patients with disease recurrence following primary treatment, PROSTATE, 39(1), 1999, pp. 54-59
Infusion of dendritic cells pulsed with HLA-A2-specific prostate-specific membrane antigen peptides: A phase II prostate cancer vaccine trial involving patients with hormone-refractory metastatic disease
Authors: Murphy, GP Tjoa, BA Simmons, SJ Jarisch, J Bowes, VA Ragde, H Rogers, M Elgamal, A Kenny, GM Cobb, OE Ireton, RC Troychak, MJ Salgaller, ML Boynton, AL
Citation: Gp. Murphy et al., Infusion of dendritic cells pulsed with HLA-A2-specific prostate-specific membrane antigen peptides: A phase II prostate cancer vaccine trial involving patients with hormone-refractory metastatic disease, PROSTATE, 38(1), 1999, pp. 73-78
Vaccine therapy for prostate cancer
Authors: Tjoa, BA Elgamal, AAA Murphy, GP
Citation: Ba. Tjoa et al., Vaccine therapy for prostate cancer, UROL CLIN N, 26(2), 1999, pp. 365
Dendritic cell-based immunotherapy for prostate cancer
Authors: Tjoa, BA Lodge, PA Salgaller, ML Boynton, AL Murphy, GP
Citation: Ba. Tjoa et al., Dendritic cell-based immunotherapy for prostate cancer, CA-A CANC J, 49(2), 1999, pp. 117
Risultati: 1-12 |